Multiple Myeloma in Relapse Recruiting Phase 2 Trials for Dexamethasone (DB01234)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03030261Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple MyelomaTreatment
NCT04063189Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple MyelomaTreatment
NCT03860038TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTreatment
NCT03155100Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment LinesTreatment
NCT03601624Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansTreatment